AI Article Synopsis
- The ventral pallidum plays a critical role in the brain's reward system, particularly influencing the activity of the ventral tegmental area (VTA).
- Research shows that the rostral ventral pallidum (RVP) is significantly activated during drug-related cues that trigger relapse, while the caudal ventral pallidum (CVP) does not show this activation.
- Disabling RVP or its connections to VTA stops cue-induced craving for cocaine, while inhibiting CVP affects cravings triggered by direct cocaine exposure, indicating that these two regions have distinct roles in addiction-related behaviors.
Article Abstract
The ventral pallidum is centrally positioned within mesocorticolimbic reward circuits, and its dense projection to the ventral tegmental area (VTA) regulates neuronal activity there. However, the ventral pallidum is a heterogeneous structure, and how this complexity affects its role within wider reward circuits is unclear. We found that projections to VTA from the rostral ventral pallidum (RVP), but not the caudal ventral pallidum (CVP), were robustly Fos activated during cue-induced reinstatement of cocaine seeking--a rat model of relapse in addiction. Moreover, designer receptor-mediated transient inactivation of RVP neurons, their terminals in VTA or functional connectivity between RVP and VTA dopamine neurons blocked the ability of drug-associated cues (but not a cocaine prime) to reinstate cocaine seeking. In contrast, CVP neuronal inhibition blocked cocaine-primed, but not cue-induced, reinstatement. This double dissociation in ventral pallidum subregional roles in drug seeking is likely to be important for understanding the mesocorticolimbic circuits underlying reward seeking and addiction.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973180 | PMC |
| http://dx.doi.org/10.1038/nn.3664 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Speech abnormalities are increasingly recognized as a manifestation of cognitive deficits in Alzheimer's disease (AD) and its preclinical and prodromal stages. Here, we investigated whether MRI measures of brain atrophy, specifically in the basal forebrain and cortical language areas, can predict cognitive decline and speech difficulties in older adults within the AD spectrum.
Method: The ongoing Prospect‐AD study aims to develop an algorithm to automatically identify speech biomarkers in individuals with early signs of AD.
Quantification of tau pathology in the basal forebrain: Associations with age, amyloid, brain structure and cognition.
Alzheimers Dement
December 2024
University of California, Berkeley, Berkeley, CA, USA
Background: Tau pathology accumulates early in the basal forebrain (BF) in Alzheimer’s disease (AD). The feasibility of measuring in vivo BF tau is unclear given PET resolution and possible partial volume effects of off‐target signal (OTS) which varies by tracer.
Method: We compared measurements of tau in cognitively unimpaired older adults with either an FTP or MK6240 scan: 93 FTP scans from the Berkeley Aging Cohort Study (BACS), 424 FTP scans from ADNI (N=517 FTP scans; 72.
Associations between basal forebrain volume and cognitive decline in GBA and LRRK2 mutation carriers from asymptomatic stages to Parkinson’s disease.
Alzheimers Dement
December 2024
DZNE, Rostock, MV, Germany
Background: In people with Parkinson’s disease (PD), mutations in GBA and LRRK2 are associated with different clinical phenotypes which might be related to differential involvement of the cholinergic system. We aimed to investigate cholinergic basal forebrain (cBF) volume in asymptomatic and symptomatic mutation carriers in comparison to idiopathic PD and healthy controls and associations with cognitive decline.
Method: This study included 149 asymptomatic GBA and 169 asymptomatic LRRK2 mutation carriers, 112 LRRK2 carriers and 60 GBA carriers with PD, 492 idiopathic PD, and 180 healthy controls from the Parkinson’s Progression Markers Initiative (PPMI).
The MRI signature of alpha‐synuclein pathology in preclinical stages and in a memory clinic population.
Alzheimers Dement
December 2024
Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden
Background: Alpha‐synuclein pathology underlies Lewy body diseases and can also occur comorbid to other neurodegenerative pathologies. The lack of an in vivo measure for alpha‐synuclein pathology until recently has limited thorough characterization of its brain atrophy pattern, especially during early disease stages. We therefore aimed to assess the association of alpha‐synuclein pathology in cerebrospinal fluid (CSF) with magnetic resonance image (MRI) structural measures in three independent cohorts, and separately in clinically unimpaired (CU) and cognitively impaired (CI) individuals, the latter reflecting a memory clinic population.
View Article and Find Full Text PDFA Neuroimaging Perspective on Familial Alzheimer's Functional Data through Bayesian Eyes.
Alzheimers Dement
December 2024
Deutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE), site Rostock / Greifswald, Rostock, Germany
Background: Familial Alzheimer's disease research necessitates innovative methodologies to disentangle the intricate relationships between genetic factors and neuroimaging measures. Traditional frequentist approaches, often hampered by small sample sizes in this population and challenges in incorporating prior knowledge transparently, may limit the robustness of findings.
Methods: We analyzed neuroimaging data of preclinical PSNE1 single mutation carriers, utilizing the software JASP to test effects of carrier status on measures of basal forebrain functional connectivity using both frequentist and Bayesian approach.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!